Search Results for: clinical-stage

By Kuldip K. Ambastha Novavax, Inc. (NVAX), a clinical-stage vaccine company, had its stock price fall by -17.2% per share on Thursday, June 9, 2022. (See past coverage if needed: “What Caught Our Attention in the Investment World? – Week of December 27-31, 2021; By Kuldip K. Ambastha.”) In 1Q2022, earnings per share plus total …

Continue reading “What Caught Our Attention in the Investment World? – Week of June 6-10, 2022”

By Kuldip K. Ambastha Novavax, Inc. (NVAX), a clinical-stage vaccine company, had four negative daily returns and one positive daily return for its shares during this past trading week per the table displayed here. Worldwide, the coronavirus pandemic continues to be a serious public health issue, especially through the Delta and Omicron COVID-19 variants. Novavax …

Continue reading “What Caught Our Attention in the Investment World? – Week of December 27-31, 2021”

By Kuldip K. Ambastha On Friday, September 3, 2021, the stock of Forte Biosciences, Inc. (FBRX) stood out for its substantial trading day loss of -82.3%. Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on potential treatments for inflammatory skin diseases. The company released results of a Phase 2 clinical trial of FB-401, related …

Continue reading “What Caught Our Attention in the Investment World? – Week of August 30-September 3, 2021”

By Kuldip K. Ambastha and Anil K. Ambastha Karuna Therapeutics Inc. (KRTX), a clinical-stage biopharmaceutical company, was founded in 2009 and is headquartered in Boston, MA. The company is focused on developing innovative therapies for individuals suffering from disabilities, disorders, and pain. Karuna Therapeutics Inc. has announced that its schizophrenia treatment’s Phase 2 clinical trial …

Continue reading “What Caught Our Attention in the Investment World? – Week of November 18-22, 2019”